Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical has proposed the adoption of a 2025 A Share Option Scheme aimed at enhancing corporate governance and establishing a long-term incentive mechanism. This scheme is designed to align the interests of shareholders and key personnel, potentially impacting the company’s operations by motivating its executive and management teams through share options.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing, manufacturing, and selling pharmaceutical products and healthcare services.
Average Trading Volume: 10,687,284
Technical Sentiment Signal: Hold
Current Market Cap: HK$76.69B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.